StockNews.AI
PCRX
StockNews.AI
168 days

PCRX Deadline: PCRX Investors Have Opportunity to Lead Pacira BioSciences, Inc. Securities Fraud Lawsuit

1. Rosen Law Firm announces Pacira class action for securities purchasers. 2. Investors may claim compensation without upfront costs through a contingency arrangement. 3. Lawsuit claims misleading statements regarding Exparel patent protections harmed investors. 4. Class Period for claims is from August 2, 2023, to August 8, 2024. 5. Lead plaintiff motion deadline is set for March 14, 2025.

6m saved
Insight
Article

FAQ

Why Very Bearish?

The lawsuit indicates significant misrepresentation of Pacira's patent position on Exparel, historically causing sharp price drops in similar cases. For example, investors often react negatively when faced with potential legal liabilities, resulting in downward pressure on stock prices.

How important is it?

The ongoing litigation and claims of misrepresentation directly affect investor sentiment and trust. Given the significant nature of the allegations and the potential for financial impact, this legal issue is highly relevant.

Why Short Term?

Immediate concerns about legal repercussions could trigger investors to sell off shares. History shows that news of lawsuits often leads to rapid market reactions.

Related Companies

EXELVRTXNBIAMGNBIIB
NEW YORK, March 4, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Pacira BioSciences, Inc. (NASDAQ: PCRX) between August 2, 2023 and August 8, 2024, both dates inclusive (the "Class Period"), of the important March 14, 2025 lead plaintiff deadline. So what: If you purchased Pacira securities during the Class Period, you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. What to do next: To join the Pacira class action, go to https://rosenlegal.com/submit-form/?case_id=33570 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than March 14, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation. Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Many of these firms do not actually litigate securities class actions, but are merely middlemen that refer clients or partner with law firms that actually litigate the cases. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers. Details of the case: According to the lawsuit, statements made during the Class Period were false and/or misleading because defendants created the false impression that Pacira had sufficient patent protections on Exparel and, as such, the ability to expand the marketing, production, and sales of Exparel, which Pacira stated was critical to its future growth and revenue. In truth, Pacira's optimistic claims pertaining to its patent protections on Exparel were fragile at best. In fact, Pacira knew that the '495 patent was not as protective as defendants publicly touted because on June 6, 2023 the New Jersey District Court issued a ruling in eVenus's favor regarding claims construction in another case filed by Pacira in a failed attempt to protect Exparel. Yet defendants continued to make public statements affirming their belief in the '495 patent and the protection it applied for Exparel. When the true details entered the market, the lawsuit claims that investors suffered damages. To join the Pacira class action, go to https://rosenlegal.com/submit-form/?case_id=33570 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff. Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm. Attorney Advertising. Prior results do not guarantee a similar outcome. Contact Information: Laurence Rosen, Esq.Phillip Kim, Esq.The Rosen Law Firm, P.A.275 Madison Avenue, 40th FloorNew York, NY 10016Tel: (212) 686-1060Toll Free: (866) 767-3653Fax: (212) 202-3827[email protected]www.rosenlegal.com SOURCE THE ROSEN LAW FIRM, P. A.

Related News